healthcap

With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.

Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales.

Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.

HealthCap’s investment objective is to achieve significant capital appreciation by focusing on diseases with high unmet medical needs and breakthrough therapies. A cornerstone of the strategy is to invest in companies developing therapeutic interventions that have the potential to significantly improve patient outcomes. HealthCap funds are looking to back companies developing targeted therapies for rare diseases (orphan drugs), cancer and genetic diseases, among others. HealthCap has substantial experience in assisting start-ups and emerging companies growing into businesses ready for initial public offerings or trade sales. HealthCap funds will not make an investment unless there are realistic avenues to make a timely exit at an attractive return.

HealthCap has raised a total of $429.3M across 3 funds, their latest being HealthCap VIII. This fund was announced on Sep 11, 2019 and raised a total of $209.3M.

Portfolio: Adcendo, Altimmune, Aro, Bonnesupport.